Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer

Apar Kishor P Ganti, Anne Kessinger

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

While basal cell carcinoma (BCC) is the most common human malignancy, distant metastases from this are rare. Current therapy for disseminated BCC is based on anecdotal reports in the absence of clinical trials to guide management. For many years, platinum based cytotoxic chemotherapy was the mainstay of treatment. Advances in the understanding of the biology of BCC have led to the development of targeted therapies (e.g. inhibitors of the hedgehog and the epidermal growth factor receptor pathways) that are currently being investigated in this disease. This review summarizes the available data on the epidemiology and management of disseminated BCC.

Original languageEnglish (US)
Pages (from-to)440-443
Number of pages4
JournalCancer Treatment Reviews
Volume37
Issue number6
DOIs
StatePublished - Oct 1 2011

Fingerprint

Basal Cell Carcinoma
Neoplasms
Therapeutics
Platinum
Epidermal Growth Factor Receptor
Epidemiology
Clinical Trials
Neoplasm Metastasis
Drug Therapy

Keywords

  • Chemotherapy
  • GDC-0449
  • Hedgehog pathway
  • Metastatic basal cell carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Systemic therapy for disseminated basal cell carcinoma : An uncommon manifestation of a common cancer. / Ganti, Apar Kishor P; Kessinger, Anne.

In: Cancer Treatment Reviews, Vol. 37, No. 6, 01.10.2011, p. 440-443.

Research output: Contribution to journalReview article

@article{a7344b134cd543229ba68dccb4869f26,
title = "Systemic therapy for disseminated basal cell carcinoma: An uncommon manifestation of a common cancer",
abstract = "While basal cell carcinoma (BCC) is the most common human malignancy, distant metastases from this are rare. Current therapy for disseminated BCC is based on anecdotal reports in the absence of clinical trials to guide management. For many years, platinum based cytotoxic chemotherapy was the mainstay of treatment. Advances in the understanding of the biology of BCC have led to the development of targeted therapies (e.g. inhibitors of the hedgehog and the epidermal growth factor receptor pathways) that are currently being investigated in this disease. This review summarizes the available data on the epidemiology and management of disseminated BCC.",
keywords = "Chemotherapy, GDC-0449, Hedgehog pathway, Metastatic basal cell carcinoma, Targeted therapy",
author = "Ganti, {Apar Kishor P} and Anne Kessinger",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.ctrv.2010.12.002",
language = "English (US)",
volume = "37",
pages = "440--443",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Systemic therapy for disseminated basal cell carcinoma

T2 - An uncommon manifestation of a common cancer

AU - Ganti, Apar Kishor P

AU - Kessinger, Anne

PY - 2011/10/1

Y1 - 2011/10/1

N2 - While basal cell carcinoma (BCC) is the most common human malignancy, distant metastases from this are rare. Current therapy for disseminated BCC is based on anecdotal reports in the absence of clinical trials to guide management. For many years, platinum based cytotoxic chemotherapy was the mainstay of treatment. Advances in the understanding of the biology of BCC have led to the development of targeted therapies (e.g. inhibitors of the hedgehog and the epidermal growth factor receptor pathways) that are currently being investigated in this disease. This review summarizes the available data on the epidemiology and management of disseminated BCC.

AB - While basal cell carcinoma (BCC) is the most common human malignancy, distant metastases from this are rare. Current therapy for disseminated BCC is based on anecdotal reports in the absence of clinical trials to guide management. For many years, platinum based cytotoxic chemotherapy was the mainstay of treatment. Advances in the understanding of the biology of BCC have led to the development of targeted therapies (e.g. inhibitors of the hedgehog and the epidermal growth factor receptor pathways) that are currently being investigated in this disease. This review summarizes the available data on the epidemiology and management of disseminated BCC.

KW - Chemotherapy

KW - GDC-0449

KW - Hedgehog pathway

KW - Metastatic basal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=79961002707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961002707&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2010.12.002

DO - 10.1016/j.ctrv.2010.12.002

M3 - Review article

C2 - 21216106

AN - SCOPUS:79961002707

VL - 37

SP - 440

EP - 443

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 6

ER -